tiprankstipranks
Advertisement
Advertisement
Alto Neuroscience: Advancing Late-Stage CNS Pipeline and Strengthened Balance Sheet Support Favorable Risk-Reward Profile
PremiumRatingsAlto Neuroscience: Advancing Late-Stage CNS Pipeline and Strengthened Balance Sheet Support Favorable Risk-Reward Profile
15d ago
Alto Neuroscience price target raised to $22 from $13 at Wedbush
Premium
The Fly
Alto Neuroscience price target raised to $22 from $13 at Wedbush
16d ago
Alto Neuroscience: Advancing Precision-Psychiatry Pipeline and De-Risked Trials Support Buy Rating
Premium
Ratings
Alto Neuroscience: Advancing Precision-Psychiatry Pipeline and De-Risked Trials Support Buy Rating
16d ago
Alto Neuroscience price target raised to $28 from $27 at BTIG
PremiumThe FlyAlto Neuroscience price target raised to $28 from $27 at BTIG
1M ago
Alto Neuroscience completes patient enrollment in ALTO-101 trial
Premium
The Fly
Alto Neuroscience completes patient enrollment in ALTO-101 trial
2M ago
Alto Neuroscience issued patent for ALTO-207
Premium
The Fly
Alto Neuroscience issued patent for ALTO-207
3M ago
Alto Neuroscience price target raised to $22 from $16 at Baird
PremiumThe FlyAlto Neuroscience price target raised to $22 from $16 at Baird
5M ago
Promising Future for Alto Neuroscience: Buy Rating Backed by Strong Financials and Clinical Advancements
Premium
Ratings
Promising Future for Alto Neuroscience: Buy Rating Backed by Strong Financials and Clinical Advancements
5M ago
Alto Neuroscience’s ALTO-207: A Promising Candidate for Treatment-Resistant Depression with Significant Financial Projections
Premium
Ratings
Alto Neuroscience’s ALTO-207: A Promising Candidate for Treatment-Resistant Depression with Significant Financial Projections
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100